Dr. Slade Matthews is a Senior Lecturer specializing in computational pharmacology and toxicology. His research focuses on predicting chemical properties and bioactivity using Python-based QSAR models and cheminformatic techniques such as molecular fingerprinting, quantum molecular calculations, clustering, and substructure analysis. He earned his PhD in 2007 on machine learning in biomedical data and has published 48 peer-reviewed papers (Scopus h-index: 18). In 2025 Slade published a state-of-the-art graph transformer-based QSAR model for Ames mutagenicity prediction. He serves on the TGA Medical and Scientific Evaluation Services Panel and the NSW Poisons Advisory Committee both since 2010. In 2024, he was elected to the ASCEPT Board and awarded Fellowship of ACTRA in 2025. Based at the University of Sydney, Slade collaborates with academic and regulatory partners to advance public safety through application of in silico toxicology and is passionate about mentoring students and interdisciplinary research bridging chemistry, biology, and data science.

Hannah Gerstmyer is an undergraduate student at the University of Sydney, currently pursuing a Bachelor of Science and Advanced Studies majoring in Chemistry and Pharmacology. Her academic interests include span materials chemistry, drug design, and cheminformatics. Hannah’s current research focuses on the cheminformatics challenges posed by substances of unknown or variable composition, complex reaction products, and biological materials (UVCBs). This work aims to assist regulatory bodies such as AICIS in linking chemical structure to bioactivity. Hannah has previously contributed to the University of Sydney’s Education Innovation program, aiding in the development and implementation of a chemical biology laboratory activity designed to foster collaborative learning and student engagement. She is passionate about bridging supramolecular chemistry, data science and drug discovery and hopes to continue exploring these areas in postgraduate research.

Tayler is an Associate Lecturer in Human Pharmacology in the School of Medical, Molecular and Forensic Sciences at Murdoch University in Perth, WA. She coordinates the school's two pharmacology units, as well as contributing to Forensic Toxicology, Veterinary Reproduction and first-year Biomedical Science units. Tayler submitted her PhD thesis earlier this year, which investigated the functional and metabolic changes that occur in male reproductive cells exposed to common herbal medicines. Her current research focuses include oocyte metabolism, and further investigation into changes in male reproductive cells exposed to herbal fertility supplements.

Georgia Bourlotos is a currently in her third year of her PhD at Flinders University in the Neurourology Research Group. She graduated with a Bachelor of Medical Science and Honours in Medical Science from Flinders University. Her research focuses on bladder cancer and improving patient outcomes and their wellbeing. Georgia has previously published a review titled “BCG induced lower urinary tract symptoms during treatment for NMIBC - Mechanisms and management strategies” (DOI: 10.3389/fnins.2023.1327053) in Frontiers in Neuroscience. She was awarded the Flinders Health and Medical Research Institute PhD Scholarship and the Australian Governement Research Training Program Scholarship. Georgia is passionate in exploring potential pathways to reduce pain in patients suffering from superficial bladder cancer.

Jing Xin has recently completed her MPhil at the University of Sydney, where she conducted research on "The Impact of Medication Regimen Complexity on Patient-Centred Outcomes in Kidney Failure." Her passion for clinical pharmacy was ignited during her previous work experience in hospital and health clinic settings. Jing is dedicated to advancing the field of nephrology and improving the care of patients with renal diseases. She is eager to contribute her knowledge and skills to make a meaningful impact in this critical area of healthcare.

Henry Purbrick is a CSIRO Industry PhD candidate at the University of Western Australia. His project is linked with Dimerix Bioscience, a Melbourne-based biopharmaceutical company, to investigate the molecular pharmacology of novel G protein-coupled receptor (GPCR) heteromers. Henry is investigating these heteromers in the context of complex inflammatory and fibrotic indications, where current therapeutics are inadequate in controlling progression. He is using live-cell biosensors, predominantly bioluminescence resonance energy transfer, to comprehensively profile the pharmacology of these heteromers. As his project is commercially orientated consideration must be made in how his research may be viably translated through to the clinic.